Erratum: Potential formula for the calculation of starting and incremental insulin glargine doses: ALOHA subanalysis (PLoS ONE (2012) 7, 8, (e41358) DOI:10.1371/journal.pone.0041358);Potential formula for the calculation of starting and incremental insulin glargine doses: ALOHA subanalysis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Kadowaki, Takashi ^a   Ohtani, Tetsuya ^b   Odawara, Masato ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b Sanofi aventis KK ^*  (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLINIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN GLARGINE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ADD ON LANTUS TO ORAL HYPOGLYCEMIC AGENTS STUDY; ADULT; ARTICLE; CORRELATION COEFFICIENT; DOSE CALCULATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RETINOPATHY; TREATMENT DURATION; TYPES OF STUDY;

EID: 84864751551     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103390     Document Type: Erratum

References (13)

1. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR, (2002) U.K. Prospective Diabetes Study Group,Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 25(2): 330-336.
2. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, et al. (2009) American Diabetes Association; European Association for Study of Diabetes; Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1): 193-203.
3. Barnett A, (2007) Dosing of insulin glargine in the treatment of type 2 diabetes. Clin Ther 29(6): 987-999.
4. Ohtani T, Ito T, (2011) Safety and effectiveness of BOT (Basal supported Oral Therapy) using insulin glargine in Japanese patients with type 2 diabetes-Results from post-marketing surveillance of insulin glargine (ALOHA study)-. Shinyaku to Rinsho (J New Rem & Clin) 60(3): 458-475.
5. Fukushima M, Suzuki H, Seino Y, (2004) Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract (Suppl 1): S37-S43.
6. Schreiber SA, Ferlinz K, Haak T, (2008) The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice. Diabetes Technol Ther 10(2): 121-127.
7. Gordon J, Pockett RD, Tetlow AP, McEwan P, Home PD, (2010) A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract 64(12): 1609-1618.
8. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, et al. (2012) Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society; International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Journal of Diabetes Investigation 3: 39-40.
9. Aday LA, Cornelius LJ, (2006) Designing and conducting health surveys: a comprehensive guide. San Francisco: Jossey-Bass.
10. Mayfield JA, White RD, (2004) Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician. 70(3): 489-500.
11. R Development Core Team (2011) R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing.
12. Holman RR, Turner RC, (1985) A practical guide to basal and prandial insulin therapy. Diabet Med 2(1): 45-53.
13. Fritsche A, Schweitzer MA, Haring HU, (2003) Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138(12): 952-959.